Weiss Ratings Reiterates "Sell (E+)" Rating for P3 Health Partners (NASDAQ:PIII)

Key Points

• Weiss Ratings has reiterated a "Sell (E+)" rating for P3 Health Partners (NASDAQ: PIII), indicating continued negative sentiment about the stock's performance.
• Lake Street Capital recently initiated coverage with a "buy" rating and a target price of $20.00, contrasting the general market sentiment.
• P3 Health Partners reported a significant EPS loss of ($6.23) for the last quarter, below analysts' expectations, amidst a negative net margin of 9.99%.

P3 Health Partners (NASDAQ:PIII - Get Free Report)'s stock had its "sell (e+)" rating restated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Lake Street Capital assumed coverage on P3 Health Partners in a research report on Thursday, August 28th. They set a "buy" rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $16.25.

P3 Health Partners Stock Down 0.8%

Shares of NASDAQ PIII opened at $8.95 on Wednesday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 0.31 and a current ratio of 0.31. The firm has a market capitalization of $64.32 million, a price-to-earnings ratio of -0.19 and a beta of 0.84. The stock has a 50 day moving average price of $8.10 and a 200 day moving average price of $7.78. P3 Health Partners has a 52-week low of $5.80 and a 52-week high of $26.00.

P3 Health Partners (NASDAQ:PIII - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($6.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.29) by ($2.94). The firm had revenue of $355.79 million during the quarter, compared to analysts' expectations of $356.52 million. P3 Health Partners had a negative net margin of 9.99% and a negative return on equity of 183.60%. P3 Health Partners has set its FY 2025 guidance at EPS. Sell-side analysts expect that P3 Health Partners will post -0.67 earnings per share for the current year.

Hedge Funds Weigh In On P3 Health Partners

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Trinity Financial Advisors LLC raised its stake in P3 Health Partners by 22.5% in the 1st quarter. Trinity Financial Advisors LLC now owns 1,278,037 shares of the company's stock worth $222,000 after acquiring an additional 234,500 shares during the last quarter. Abundance Wealth Counselors raised its stake in P3 Health Partners by 77.3% in the 1st quarter. Abundance Wealth Counselors now owns 400,000 shares of the company's stock worth $66,000 after acquiring an additional 174,395 shares during the last quarter. Finally, Cresset Asset Management LLC raised its stake in P3 Health Partners by 33.3% in the 1st quarter. Cresset Asset Management LLC now owns 200,000 shares of the company's stock worth $33,000 after acquiring an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 7.75% of the company's stock.

About P3 Health Partners

P3 Health Partners Inc, a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc was founded in 2020 and is based in Henderson, Nevada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.